The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Evaluating patient suitability for zolbetuximab in gastroesophageal cancer
Samuel Klempner, MD, Massachusetts General Hospital, Boston, MA, discusses several clinical factors, such as comorbidities and performance status, that should be considered before offering the anti-claudin 18.2 monoclonal antibody zolbetuximab to patients. Despite these, with careful management, these factors should not prevent the prescription of zolbetuximab, particularly given the strong evidence from Phase III trials consistently showing improved overall and progression-free survival in patients. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
